Rhumbline Advisers Grows Holdings in MiMedx Group, Inc $MDXG

Rhumbline Advisers raised its holdings in shares of MiMedx Group, Inc (NASDAQ:MDXG) by 1.4% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 177,156 shares of the company’s stock after purchasing an additional 2,436 shares during the quarter. Rhumbline Advisers owned 0.12% of MiMedx Group worth $1,346,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in the stock. Millennium Management LLC increased its stake in MiMedx Group by 93.9% in the 1st quarter. Millennium Management LLC now owns 1,230,984 shares of the company’s stock worth $9,355,000 after buying an additional 596,016 shares during the period. Meros Investment Management LP grew its stake in MiMedx Group by 107.7% in the 1st quarter. Meros Investment Management LP now owns 820,605 shares of the company’s stock worth $6,237,000 after acquiring an additional 425,531 shares in the last quarter. Nuveen LLC purchased a new position in shares of MiMedx Group during the first quarter worth approximately $2,355,000. Phocas Financial Corp. purchased a new position in shares of MiMedx Group during the fourth quarter worth approximately $2,016,000. Finally, Goldman Sachs Group Inc. raised its stake in shares of MiMedx Group by 22.7% during the first quarter. Goldman Sachs Group Inc. now owns 1,121,814 shares of the company’s stock valued at $8,526,000 after acquiring an additional 207,397 shares in the last quarter. 79.15% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research analysts recently issued reports on MDXG shares. Wall Street Zen raised MiMedx Group from a “hold” rating to a “strong-buy” rating in a research note on Saturday, August 2nd. Cantor Fitzgerald upped their target price on MiMedx Group from $11.00 to $12.00 and gave the stock an “overweight” rating in a report on Thursday, July 31st. One equities research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Down 1.8%

MDXG opened at $7.02 on Friday. The company has a market cap of $1.04 billion, a PE ratio of 33.43 and a beta of 1.74. MiMedx Group, Inc has a twelve month low of $5.47 and a twelve month high of $10.14. The company has a 50-day moving average price of $7.00 and a 200 day moving average price of $6.93. The company has a quick ratio of 3.90, a current ratio of 4.39 and a debt-to-equity ratio of 0.08.

MiMedx Group (NASDAQ:MDXG) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.04. MiMedx Group had a return on equity of 23.03% and a net margin of 8.84%.The company had revenue of $98.61 million for the quarter, compared to analysts’ expectations of $90.79 million. Sell-side analysts expect that MiMedx Group, Inc will post 0.3 earnings per share for the current fiscal year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.